Daily Chart

Glaxosmithkline Plc-spon Adr (GSK) Financial News - Glaxo Halts Resveratrol Study

Glaxosmithkline Plc-spon Adr (GSK)

Glaxo Halts Resveratrol Study

Keywords: Glaxo Smith Kline resveratrol, multiple myeloma study, Sirtris Pharmaceuticals
Quote: GlaxoSmithKline (GSK) halted a clinical trial seeking toexplore the benefits of a chemical found in red wine.The trial was studying the effects on cancer patients of a drug containing a reformulated version of resveratrol. Glaxoacquired the drug as part of its 2008 purchase of Sirtris Pharmaceuticals.Glaxo halted its trial of the drug on patients with multiple myeloma  after several patients developed nephropathy,a condition that can cause kidney failure.A Sirtris official told Dow Jones that the condition is common in multiple myeloma patients, so its cause is unclear.Resveratrol has been hailed as an anti-aging miracle drug, but recently scientists have begun to question the effectiveness.Resveratrol is thought to work by activating enzymes in the body called sirtuins....
Open whole article (external link)

Other Financial and Stock Market News concerning Glaxosmithkline Plc-spon Adr

Glaxosmithkline Plc-spon Adr Stock Summary

Stocktweeting is not a financial advisor, and in no way recommends the purchase of any stock or advise on the suitability of any trade or investment.
Stock trading and investing can cause loss of capital, and you should always consult with a professional financial advisor before trading or investing.

This website is a service of the HagensMedia ad network. For advertising please visit http://www.hagensmedia.com - Copyright 2015.